Paolo Marcucci, President and CEO of Kedrion, has joined the Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA).<\/p>\n
“We are excited that Mr. Marcucci is joining the Global Board of Directors”<\/em> said Jan M. Bult, PPTA’s President. “Paolo Marcucci understands the many challenges confronting our industry and the patients we serve. He is a leader dedicated to advancing the plasma protein therapeutics industry to meet the needs in the 21st century of a global population depending on the critical, life-saving medicines produced by PPTA members”.<\/em><\/p>\n Paolo Marcucci has been President of Kedrion since 2003 and CEO of Kedrion since 2006. He began his career in the pharmaceuticals industry in 1991.<\/p>\n Giovanni Rinaldi, Kedrion's Institutional Affairs Director, has been appointed President of PPTA Europe, the European association of manufacturers of plasma-derived products. In addition, Mr Rinaldi is a member of the Global Management Commitee, PPTA Global's Executive Committee.<\/p>\n The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world’s major producers of plasma-derived and recombinant analog therapies (collectively, “plasma therapies”). These therapies are used by over 1,000,000 worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, immune globulin intravenous used to prevent infections in people with immune deficiencies and other serious conditions.<\/p>\n